Publication year | Country | Center | Number | Regimen | ITT cure rate | PP cure rate | Adverse reaction rate |
---|---|---|---|---|---|---|---|
2005 [10] | Spain | single | 12 | PPI + CLA + MET 7 days | 58% | 64% | 17% |
2005 [31] | Puerto Rico | single | 17 | PPI + TET + MET 10 days | 84% | 84% | unavailable |
2006 [32] | Japan | single | 5 | PPI + TET + MET 7–14 days | 80% | 100% | unavailable |
2010 [11] | Spain | multiple | 50 | PPI + CLA + MET 7 days | 54% | 55% | 10% |
2014 [33] | Japan | single | 11 | PPI + MET+SIT 7–14 days | 100% | 100% | 64% |
2015 [9] | Spain | multiple | 112 | PPI + CLA + MET 7 days | 57% | 59% | 14% |
50 | PPI + TET + MET+BIS 10 days | 74% | 75% | 14% | |||
2017 [12] | Japan | single | 10 | PPI + CLA + MET 7 days | 50% | 56% | unavailable |
13 | VPZ + CLA + MET 7 days | 92% | 92% | unavailable | |||
20 | PPI + MET+SIT 7 days | 100% | 100% | unavailable | |||
14 | VPZ + MET+SIT 7 days | 93% | 100% | unavailable |